Association of skin autofluorescence with low bone density/osteoporosis and osteoporotic fractures in type 2 diabetes mellitus

Hongyan Liu, Guoqi Wang, Ting Wu, Jia Hu, Yiming Mu, Weijun Gu

1Department of Endocrinology, The First Medical Center of Chinese PLA General Hospital, Beijing, China
2Department of Pediatrics, The First Medical Center of Chinese PLA General Hospital, Beijing, China

Correspondence
Yiming Mu and Weijun Gu, Department of Endocrinology, The First Medical Center of Chinese PLA General Hospital, 100853, Beijing, China. Email: muyiming@301hospital.com and guweijun301@163.com

Funding information
Study on the prevalence, nutrition and influencing factors of diabetes, Grant/Award Number: 2016YFC1305200; National Key R&D Program of China

Abstract

Background: Advanced glycation end products (AGEs) that abnormally accumulate in diabetic patients have been reported to damage bone health. We aimed to investigate the association between skin autofluorescence (SAF)-AGEage (SAF – AGEs × age/100) and low bone density (LBD)/osteoporosis or major osteoporotic fractures (MOFs) in patients with type 2 diabetes mellitus (T2DM).

Methods: This study was nested in the prospective REACTION (Risk Evaluation of Cancers in Chinese Diabetic Individuals) study and included 1214 eligible participants. SAF was used to measure skin AGEs (SAF-AGEs). Fracture events were determined by an in-person clinical follow-up. Binary logistic regression analysis, linear regression analysis, and a restricted cubic spline nested in logistic models were used to test outcomes.

Results: The overall prevalence of LBD/osteoporosis in middle-aged or elderly T2DM patients was 35.7% (n = 434), and the overall incidence of MOFs was 10.5% (n = 116). Logistic analysis showed a significantly positive relationship between quartiles of SAF-AGEage and the risk of LBD/osteoporosis (odds ratio [OR] 2.02, 95% CI 1.34–3.03; OR 3.63, CI 2.44–5.39; and OR 6.51, CI 4.34–9.78) for the multivariate-adjusted models, respectively. SAF-AGEage was associated with MOFs with a multivariate-adjusted OR of 1.02 (CI 0.52–2.02), 2.42 (CI 1.32–4.46), and 2.70 (CI 1.48–4.91), respectively. Stratified analyses showed that SAF-AGEage was significantly associated with MOFs only in females, non-smokers, nondrinkers, individuals with lower body mass index, and those without LBD/osteoporosis. Linear regression analyses showed that higher SAF-AGEs were associated with a higher level of serum N-terminal propeptide of type I procollagen (s-PINP) and serum carboxy-terminal cross-linking peptide of type I collagen (s-CTX), with a multivariate-adjusted OR of 1.02 (CI 0.24–1.80) and 6.30 (CI 1.77–10.83), respectively.
Conclusions: In conclusion, SAF-AGE_{age} was positively associated with the prevalence of LBD/osteoporosis or MOFs in patients with T2DM. A positive association between SAF-AGEs and the level of s-PINP and s-CTX was found.

**KEYWORDS**
advanced glycation end products (AGEs), bone turnover, osteoporosis, osteoporotic fractures, type 2 diabetes mellitus (T2DM)

**Highlights**
- The association between skin autofluorescence advanced glycation end products (SAF-AGE_{age}) and low bone density/osteoporosis or major osteoporotic fractures was noteworthy in patients with type 2 diabetes mellitus (T2DM).
- SAF-AGEs were positively associated with the level of serum N-terminal propeptide of type I procollagen (s-PINP) and serum carboxy-terminal cross-linking peptide of type I collagen (s-CTX).
- To our knowledge, this is the first article that reports the association between SAF-AGEs and bone turnover markers in patients with T2DM.

1 | INTRODUCTION

Osteoporosis is an important complication of type 2 diabetes mellitus (T2DM) and the most common systemic bone disease. It is characterized by low bone mass and microstructural damage to bone tissue\(^1\) that manifests with increased bone fragility and an increased risk of fracture.\(^2\) Prior work has shown osteoporotic fractures are particularly common in the vertebral bodies.\(^3\) Osteoporosis-related bone fractures pose one of the important risks for disability and death in the elderly and have thus received growing attention. It has been reported that around 40% of mainland Chinese T2DM patients have osteoporosis\(^4\) and are at a significantly higher risk of bone fracture than healthy individuals.\(^5\)

Advanced glycation end products (AGEs) are stable and irreversible heterogeneous compounds that are formed nonenzymatically as a result of Maillard or browning reactions. Identified structures include pentosidine, carboxymethyllysine (CML), pyrraline, and crossline.\(^6\) AGEs, as the physiological products of the life cycle, accumulate abnormally in diabetic patients due to persistent hyperglycemia and other pathological changes. AGEs can affect the structures and function of proteins and cause tissue damage by trapping and cross-linking structural and blood proteins directly or indirectly, especially collagens.\(^7,8\) Type I collagen is a key component of the bone matrix. It has been demonstrated that in vitro, the synthesis and secretion of osteocalcin and type I collagen of osteoblasts decreased significantly when AGE-bovine serum albumin (BSA) was added to the culture medium.\(^9\) Hein et al. reported that in osteoporotic patients compared with healthy subjects, the serum concentrations of pentosidine and CML are increased and that pentosidine may increase bone resorption of osteoclasts.\(^10\) The study by Choi D. H. et al found an association between increased serum pentosidine levels and reduced bone mineral density (BMD) or osteoporotic fractures in patients without DM.\(^11\)

Skin autofluorescence (SAF) is a noninvasive method to measure skin AGEs (SAF-AGEs). A close relationship has been demonstrated between the SAF-AGEs value and that obtained via a skin biopsy.\(^12,13\) Tabara et al found that SAF-AGEs are associated with reduced BMD, low skeletal muscle mass, and weak muscle strength in the general population (with or without DM).\(^14\) The Rotterdam Study demonstrated that subjects with osteoporotic fractures had higher SAF-AGE values\(^15\).

There are few studies investigating the relationship between BMD or osteoporotic fractures and AGEs in patients with T2DM. Given the importance of age on AGEs and osteoporosis or osteoporotic fractures, we used the age-combined SAF-AGE (SAF-AGE_{age}) index \((SAF – AGEs \times age/100)\) in the related investigation of AGEs and osteoporosis or osteoporotic fractures in our study. Our main aim was to investigate the association between SAF-AGE_{age} and low bone density (LBD)/osteoporosis or osteoporotic fractures in patients with T2DM and to test how AGEs affect bone turnover. The influence of age on bone turnover markers is not known, so the SAF-AGEs
index instead of the SAF-AGE\textsubscript{age} index was used in the related study of AGEs and bone turnover.

2 | METHODS

2.1 | Study population and design

The present study was nested in the REACTION (Risk Evaluation of Cancers in Chinese Diabetic Individuals) study, an ongoing multicenter prospective cohort study designed to research the relationship between T2DM and prediabetes with the risk of cancer in the People's Republic of China; details have been described previously.\textsuperscript{16} The study protocol was approved by the Committee on Human Research at the Chinese People's Liberation Army (PLA) General Hospital, and written informed consent was obtained from all participants prior to participation. For our study, 6854 participants aged 40 years or older were recruited in central Beijing between September and December 2018. T2DM was diagnosed according to the 1999 World Health Organization (WHO) criteria. The exclusion criteria of our study were (1) a diagnosis of hyperparathyroidism, hyperthyroidism, end-stage kidney disease, rheumatic disease (such as rheumatoid arthritis, systemic lupus erythematosus, etc.), psychiatric disorder, severe liver dysfunction, or cancers that might affect bone metabolism; (2) no diagnosis of T2DM; (3) current use of glucocorticoids, steroid hormones, antiepileptic drugs, chemotherapy drugs, antiviral drugs, or proton pump inhibitor use within 3 months; and (4) individuals without complete requisite data. Based on these criteria, the final cohort included 1214 eligible participants.

2.2 | Measurement of SAF

A spectroscopy device (AGE Reader, Hefei Institutes of Physical Science, Chinese Academy of Sciences) was used to measure skin AGEs. The AGE Reader is a noninvasive instrument that quantifies AGEs based on their fluorescent properties (excitation is at 300–420 nm and emission at 420–600 nm). An excitation light source with a peak wavelength of 370 nm was used to illuminate a 1–4-cm section of the forearm. Local creams or lotions were withheld for 12 h before the examination, and the participant was instructed to stay immobile during the acquisition time (around 30 s). The emitted and reflected light was measured by the AGE Reader. The AGE Reader software automatically calculated SAF based on the ratio between the emitted and reflected light. Three examinations were conducted by trained operators, and an average score was obtained for statistical analysis.

2.3 | Measurement of BMD

BMD was measured via dual-energy X-ray absorptiometry (DXA) using a Lunar Prodigy DXA bone densitometer (GE Lunar Corp, Madison, Wisconsin) and expressed in g/cm\textsuperscript{2}. The main measurement sites were the lumbar spine (L1–L4), total hip, and femoral neck. The distal radius was utilized if the three main sites proved difficult to measure. The scans were conducted by a single trained technician and assessed by a third specialist if necessary. T-scores were calculated based on the measured BMD value and peak BMD value from normal young people of the same race and sex. According to the diagnostic criteria recommended by the WHO, osteoporosis was defined as a T-score below $-2.5$, and LBD was defined as a T-score between $-1.0$ and $-2.5$.

2.4 | Confirmation of major osteoporotic fractures

Follow-up for fracture events was continued until 31 March 2022. Locations of osteoporotic fractures were classified as home or workplace/shopping mall. Reasons for osteoporotic fractures were classified as a “minor external force collision” or a “fall.” Sites of major osteoporotic fractures (MOFs) included the vertebra, hip, wrist, or humerus. All fracture events were diagnosed by clinicians and confirmed by radiographs in a grade A tertiary hospital.

2.5 | Clinical examinations

Each individual was comprehensively examined including a detailed questionnaire, routine physical examinations, a standard 75-g oral glucose tolerance test (OGTT)/100-g steamed-bread meal test (SBMT), and laboratory measurements. The content of the questionnaire included age, sex, smoking status, drinking status, eating habits, physical exercise, sleep, medical history, familial medical history, medication history, surgical history, etc. Current smoking was defined as smoking more than once daily within the last 3 months. Current drinking was defined as recent drinking of nearly/more than once a week. Eating habits mainly referred to daily salt intake and were classified as greater or less than 6 g. Familial medical history included that of first-degree relatives. Height (cm), weight (kg), waist circumference (cm), and hip circumference (cm) were measured in a standard standing position wearing light clothing without shoes and recorded to one decimal point. Body mass index (BMI) was calculated as the weight (kg) divided
by the height (m) squared (kg/m²). Waist to hip ratio (WHR) was calculated as waist circumference (cm) divided by hip circumference (cm). Blood pressure was measured in a standard sitting position, three times every 5 min, and an average value was used for statistical analysis.

2.6 | Laboratory measurements

Venous blood samples were collected between 8 and 9 AM following a 24-hour fast. A standard 75-g OGTT was used for subjects without DM, and a 100-g SBMT was used for subjects with DM. Serum N-terminal propeptide of type I procollagen (s-PINP) and serum carboxy-terminal cross-linking peptide of type I collagen (s-CTX) were determined by an electrochemiluminescence assay (Elecsys, Roche Diagnostics, Basel, Switzerland). Fasting blood glucose, 2-hour postload blood glucose, serum triglycerides (TGs), total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, uric acid, calcium, and phosphorus were measured using an autoanalyzer (Cobas 8000 modular analyzer series; Roche Diagnostics, Basel, Switzerland). Glycosylated hemoglobin (HbA1c) was determined by a high-performance liquid chromatography method using the VARIANT II Hemoglobin Testing System (Tosoh Corporation, Tokyo, Japan).

2.7 | Statistical analysis

Continuous variables are expressed as the mean ± SD, and categorical variables are expressed as frequency and percentage. Continuous variables were compared using the t test (for data conforming to normal distribution and homogeneity of variance) or Wilcoxon test or Kruskal-Wallis H test (for data not conforming to normal distribution or homogeneity of variance). Categorical variables were compared using the chi-square test. Statistical significance was determined by p < 0.05. Binary logistic regression analysis was conducted to test the relationships between the prevalence of LBD/osteoporosis or MOFs and quartiles of SAF-AGEage. A restricted cubic spline nested in logistic models was used to observe the dose-response relationship between SAF-AGEage and the incidence of LBD/osteoporosis or MOFs. Linear regression analysis was conducted to test the relationships between SAF-AGEages and bone turnover markers (s-PINP and s-CTX), IBM SPSS statistics (version 25.0; SPSS, Inc, Chicago, Illinois) and R (http://www.R-project.org; The R Foundation) software were used to perform all analyses.

3 | RESULTS

3.1 | Clinical characteristics

Table 1 summarizes the clinical characteristics of the 1214 enrolled participants with T2DM by LBD/osteoporosis status. The overall prevalence of LBD/osteoporosis in these middle-aged or elderly T2DM patients was 35.7% (n = 434). Mean SAF-AGEage in groups with and without LBD/osteoporosis was 51.50 ± 9.36 and 45.56 ± 7.62, respectively (p < 0.0001). We also found that the incidence of LBD/osteoporosis increased gradually with increasing SAF-AGEage (Figure 1). T2DM patients with LBD/osteoporosis were significantly more likely to be female and older, to have higher diastolic blood pressure (DBP), fasting plasma glucose (FPG), and serum calcium and phosphorus, and lower WHR (all p < 0.05). Moreover, patients with T2DM who currently smoked and drank, had hypertension, took antihypertensives, or lipid-lowering drugs had a significantly higher incidence of LBD/osteoporosis. There was no significant difference in other characteristics between the two groups (all p > 0.05).

In total, 1101 (90.7%) individuals completed the MOF follow-up. The overall prevalence of MOFs in middle-aged or elderly T2DM patients was found to be 10.5% (n = 116). Mean SAF-AGEage in groups with and without MOFs was 50.19 ± 8.23 and 47.55 ± 8.69, respectively (p = 0.002). T2DM patients who smoked had a significantly higher prevalence of MOFs (18.1% vs 8.3%, p < 0.001). More detailed characteristics of the two groups are shown in Table 2.

3.2 | Association between SAF-AGEage and LBD/osteoporosis

The univariate binary logistic analysis with SAF-AGEage as a categorical variable showed a significantly positive relationship between SAF-AGEage and the risk of LBD/osteoporosis; SAF-AGEage Q2 versus Q1 showed an odds ratio (OR) of 1.95 (95% CI 1.33–2.87), SAF-AGEage Q3 versus Q1 was 3.12 (2.14–4.54), and SAF-AGEage Q4 versus Q1 was 6.51 (4.34–9.78). After adjusting for sex, BMI, WHR, systolic blood pressure (SBP), DBP, FPG, 2-hour PG, hypertension history, current smoking, current drinking, use of calcium channel blockers (CCBs), angiotensin receptor blockers (ARBs), angiotensin-converting enzyme inhibitors (ACEIs), statins, calcium, or calcitriol the ORs (95% CI) were 2.02 (1.34–3.03), 3.63 (2.44–5.39), and 6.51 (4.34–9.78), respectively (Table 3).

Logistic analysis with SAF-AGEage as a continuous variable also showed a significant association, with an
| Risk Factor                  | Total N = 1214 | Without LBD/osteoporosis n = 780 | With LBD/osteoporosis n = 434 | p      |
|-----------------------------|----------------|----------------------------------|-------------------------------|--------|
| **Age, y**                  | 64.7 (7.5)     | 64.24 (7.5)                      | 65.51 (7.5)                   | 0.005  |
| Gender male, n (%)          | 441 (40%)      | 310 (40%)                        | 131 (30%)                     | 0.002  |
| Menopause (only female), n (%) | 757 (97.9%)    | 459 (97.7%)                      | 298 (98.3%)                   | 0.510  |
| Age at menopause, y         | 49.57 (4.14)   | 49.55 (4.21)                     | 49.62 (4.01)                  | 0.843  |
| BMI, kg/m²                  | 25.1 (3.3)     | 25.2 (3.3)                       | 24.9 (3.3)                    | 0.435  |
| WHR                         | 0.78 (0.10)    | 0.79 (0.10)                      | 0.77 (0.09)                   | 0.002  |
| SBP, mmHg                   | 127.70 (29.43) | 128.15 (34.72)                   | 126.90 (16.01)                | 0.481  |
| DBP, mmHg                   | 78.38 (10.06)  | 79.14 (10.34)                    | 77.01 (9.39)                  | <0.0001|
| FPG, mmol/L                 | 5.9 (1.7)      | 5.87 (1.58)                      | 6.08 (1.83)                   | 0.041  |
| 2-h PG, mmol/L              | 6.6 (4.2)      | 6.45 (3.93)                      | 6.87 (4.54)                   | 0.099  |
| HbA1c (%)                   | 7.81 (1.71)    | 7.80 (1.72)                      | 7.85 (1.70)                   | 0.579  |
| Diabetes duration, y        | 10.9 (8.6)     | 10.50 (8.349)                    | 11.49 (8.98)                  | 0.056  |
| TC, mmol/L                  | 5.4 (1.0)      | 5.38 (0.97)                      | 5.33 (1.04)                   | 0.412  |
| HDL-C, mmol/L               | 1.5 (0.4)      | 1.50 (0.344)                     | 1.48 (0.35)                   | 0.384  |
| LDL-C, mmol/L               | 5.4 (3.6)      | 5.36 (3.39)                      | 5.61 (3.95)                   | 0.241  |
| Ca, mmol/L                  | 2.3 (0.1)      | 2.25 (0.10)                      | 2.27 (0.12)                   | 0.002  |
| P, mmol/L                   | 1.2 (0.1)      | 1.15 (0.15)                      | 1.17 (0.15)                   | 0.026  |
| UA, µmol/L                  | 319.4 (76.4)   | 322.16 (76.05)                   | 314.56 (76.81)                | 0.097  |
| AGEage                      | 47.7 (8.8)     | 45.56 (7.62)                     | 51.50 (9.36)                  | <0.0001|
| Current smoking, n (%)      | 267 (22.0%)    | 150 (19.2%)                      | 117 (27.0%)                   | 0.002  |
| Current drinking, n (%)     | 133 (10.9)     | 189 (24.2%)                      | 131 (30.2%)                   | 0.024  |
| Hypertension, n (%)         | 732 (60.3%)    | 454 (58.2%)                      | 278 (64.1%)                   | 0.049  |
| Hyperlipidemia, n (%)       | 565 (46.5%)    | 363 (46.5%)                      | 202 (46.5%)                   | 0.999  |
| Hyperuricemia, n (%)        | 77 (6.3%)      | 56 (7.2%)                        | 21 (4.8%)                     | 0.109  |
| Hypertension family history, n (%) | 755 (62.1%) | 486 (62.3%)                      | 269 (62.0%)                   | 0.911  |
| Diabetes family history, n (%) | 690 (56.8%) | 455 (58.2%)                      | 236 (54.4%)                   | 0.197  |

**Antidiabetic agents, n (%)**

- **Oral antidiabetes drugs**
  - Metformin: 602 (49.5%), 400 (51.3%), 202 (46.5%), 0.114
  - Sulfonlureas: 144 (11.9%), 91 (11.7%), 53 (12.2%), 0.778
  - Thiazolidinediones: 8 (0.7%), 7 (0.9%), 1 (0.2%), 0.314
  - Glinides: 10 (0.8%), 8 (1.0%), 2 (0.5%), 0.476
  - DPP-IV inhibitors: 6 (0.5%), 6 (0.8%), 0
  - Glycosidase inhibitors: 606 (49.9%), 399 (51.2%), 207 (44.7%), 0.248
  - SGLT2 inhibitors: 0, 0, 0
  - GLP-1 receptor agonists: 12 (1.0%), 9 (1.2%), 3 (0.7%), 0.633
- **Insulin**: 309 (25.4%), 194 (24.9%), 115 (26.5%), 0.533

**Antihypertension agents, n (%)**

- **Ca channel blockers**: 651 (53.6%), 435 (55.8%), 216 (49.8%), 0.045
- **Angiotensin receptor blockers**: 428 (35.3%), 294 (37.7%), 134 (39%), 0.017
- **Angiotensin-converting enzyme inhibitors**: 208 (17.1%), 158 (20.3%), 50 (11.5%), <0.0001

(Continues)
OR (95% CI) of 2.11 (1.84–2.43) per SD increase of SAF-AGE<sub>age</sub> in the crude model and 2.22 (1.90–2.58) in the multivariate adjusted model (both p for trend <0.001) (Table 3). When restricted cubic splines were used in the logistic model with SAF-AGE<sub>age</sub> as a continuous variable, a graded positive relationship was also observed between the incidence of LBD/osteoporosis and SAF-AGE<sub>age</sub> (Figure 2).

Stratified analyses were conducted according to sex, BMI, current smoking, current drinking, and family history of diabetes. The results were similar across all subgroups and in accordance with that identified in the whole group (Table 3). No interactions were observed when tested by subgroup analyses.

### 3.3 Association between SAF-AGE<sub>age</sub> and MOFs

The ORs (95% CI) of MOFs across SAF-AGE<sub>age</sub> quartiles were 1.12 (0.58–2.17), 2.24 (1.24–4.04), and 2.51 (1.40–4.49) in the crude model and 1.02 (0.52–2.02), 2.42 (1.32–4.46), and 2.70 (1.48–4.91) in the multivariate-adjusted model including sex, BMI, DBP, hypertension, current smoking, current drinking, CCB, statins, and serum TGs (Table 4).

Logistic analysis with SAF-AGE<sub>age</sub> as a continuous variable also showed a significant association with an OR (95% CI) of 1.31 (1.10–1.56) per SD increase of SAF-AGE<sub>age</sub> in the crude model (p for trend = 0.003) and 1.39 (1.15–1.67)
| TABLE 2         | Total N = 1101 | Without MOFs n = 985 | With MOFs n = 116 | p      |
|-----------------|----------------|----------------------|-------------------|--------|
| Age, y          | 64.71 (7.54)   | 64.40 (7.40)         | 67.36 (8.21)      | <0.001 |
| Gender male, n (%) | 395 (35.9%)   | 357 (36.2%)         | 38 (32.8%)       | 0.459  |
| Menopause (only female), n (%) | 693 (98.2%) | 616 (98.1%)   | 77 (98.7%)       | 0.697  |
| Age at menopause, y | 49.62 (4.16) | 49.57 (4.24)       | 50.03 (3.45)     | 0.374  |
| BMI, kg/m²      | 25.10 (3.32)   | 25.14 (3.30)        | 24.75 (3.44)      | 0.237  |
| WHR             | 0.78 (0.10)    | 0.78 (0.10)         | 0.78 (0.08)       | 0.912  |
| SBP, mm Hg      | 126.98 (16.45) | 126.81 (16.39)      | 128.43 (16.89)   | 0.317  |
| DBP, mm Hg      | 78.46 (9.90)   | 78.22 (9.78)        | 80.51 (10.71)     | 0.019  |
| FPG, mmol/L     | 5.94 (1.68)    | 5.93 (1.66)         | 6.05 (1.92)       | 0.459  |
| 2-h PG, mmol/L  | 6.64 (4.20)    | 6.65 (4.13)         | 6.57 (4.75)       | 0.855  |
| Diabetes duration, y | 10.81 (8.54) | 10.77 (8.58) | 11.14 (8.19) | 0.662  |
| TC, mmol/L      | 5.36(0.99)     | 5.36(1.01)          | 5.39(0.90)        | 0.736  |
| TGs, mmol/L     | 1.75(1.58)     | 1.71(1.34)          | 2.03(2.90)        | 0.039  |
| HDL-C, mmol/L   | 1.49(0.35)     | 1.49(0.35)          | 1.48(0.34)        | 0.781  |
| LDL-C, mmol/L   | 5.43(3.61)     | 5.40(3.57)          | 5.68(3.97)        | 0.431  |
| Ca, mmol/L      | 2.25(0.11)     | 2.25(0.11)          | 2.25(0.10)        | 0.637  |
| P, mmol/L       | 1.16(0.15)     | 1.16(0.15)          | 1.15(0.15)        | 0.553  |
| UA, μmol/L      | 318.37 (75.44) | 317.10 (74.40)      | 329.13 (83.30)   | 0.104  |
| AGEage          | 47.83 (8.68)   | 47.55 (8.69)        | 50.19 (8.23)      | 0.002  |
| Current smoking, n (%) | 249 (22.6%) | 204 (20.7%)   | 45 (38.8%)       | <0.001 |
| Current drinking, n (%) | 284 (25.8%) | 247 (25.1%) | 37 (31.9%) | 0.112  |
| Hypertension, n (%) | 667 (60.6%) | 586 (59.5%) | 81 (69.8%) | 0.031  |
| Hyperlipidemia, n (%) | 514 (46.7%) | 453 (46.0%) | 61 (52.6%) | 0.178  |
| Hyperuricemia, n (%) | 68 (6.2%) | 62 (6.3%)   | 6 (5.2%)        | 0.635  |
| Hypertension family history, n (%) | 682 (61.9%) | 605 (61.4%) | 77 (66.4%) | 0.298  |
| Diabetes family history, n (%) | 632 (57.4%) | 569 (57.8%) | 63 (54.3%) | 0.476  |
| **Antidiabetic agents, n (%)** | | | | |
| Oral antidiabetes drugs | 925 (84.0%) | 825 (83.8%) | 100 (86.2%) | 0.496  |
| Metformin       | 545 (49.5%)   | 490 (49.7%)        | 55 (47.4%)        | 0.635  |
| Sulfonylureas   | 127 (11.5%)   | 115 (11.7%)        | 12 (10.3%)        | 0.671  |
| Thiazolidinediones | 8 (0.7%) | 8 (0.8%)   | 0               |        |
| Glinides        | 9 (0.8%)      | 8 (0.8%)           | 1 (0.9%)          |        |
| DPP-IV inhibitors | 6 (0.5%) | 4 (0.4%)   | 2 (1.7%)        |        |
| Glycosidase inhibitors | 553 (50.2%) | 489 (49.6%) | 64 (55.2%) | 0.260  |
| SGLT2 inhibitors | 0              | 0                  | 0               |        |
| GLP-1 receptor agonists | 10 (0.9%) | 8 (0.8%)   | 2 (1.7%)        |        |
| Insulin         | 276 (25.1%)   | 248 (25.2%)        | 28 (24.1%)        | 0.807  |
| **Antihypertension agents, n (%)** | | | | |
| Ca channel blockers | 591 (53.7%) | 521 (52.9%) | 70 (60.3%) | 0.128  |
| Angiotensin receptor blockers | 388 (35.2%) | 339 (34.4%) | 49 (42.2%) | 0.095  |
| Angiotensin-converting enzyme inhibitors | 189 (17.2%) | 166 (16.9%) | 23 (19.8%) | 0.422  |
| β-receptor blocker | 43 (3.9%) | 41 (4.2%)   | 2 (1.7%)        | 0.304  |
| Diuretics       | 50 (4.5%)     | 44 (4.5%)          | 6 (5.2%)          | 0.730  |

(Continues)
In vitro experiments have found that AGEs may change osteoporosis, or had a BMI < 25 (OR 1.51, CI 1.21–1.88, p = 0.001), but not in patients who smoked or had LBD/osteoporosis, or a BMI ≥ 25 (OR 1.26, CI 0.89–1.80, p = 0.199; OR 1.23, CI 0.87–1.72, p = 0.238; OR 1.17, CI 0.85–1.60, p = 0.332; and OR 1.23, CI 0.94–1.61, p = 0.126). Subgroup analyses showed no interaction effects between SAF-AGE and sex, BMI, current smoking, or current drinking in fully adjusted models.

4 | DISCUSSION

In the present study, we report that SAF-AGEage is closely associated with the incidence of LBD/osteoporosis in patients with T2DM. Moreover, with the categories of increasing SAF-AGEage, the incidence of LBD/osteoporosis gradually increased. This trend existed among patients of different sexes, BMI, smoking and drinking status, and family history of diabetes. There are few published studies examining the relationship between BMD and AGEs in patients with T2DM. Raška et al found no relationship between serum circulating receptors of AGES and BMD in postmenopausal women with T2DM.17 Yavuz et al found that osteoporotic patients with T2DM have a higher SAF-AGE level, which is consistent with our results.18 A series of studies have found that AGES can influence the structure and function of type I collagen, an important component of bone mass.19–21 AGES may change the osteoblasts and osteoclast capacity for bone turnover by inducing chronic inflammation, thereby degrading bones and changing BMD.22

We found a positive association of SAF-AGES with s-PINP and s-CTX. It is well-known that the rate of bone turnover in T2DM patients is lower compared with healthy individuals.23–25 In vitro experiments have found that AGEs can adversely affect osteoclast and osteoblast differentiation and function and decrease bone turnover.26–28 Lamb et al. found that the plasma endogenous secretory receptor for AGES (esRAGE) is positively related to PINP in old men with or without T2DM.29 Eckhardt et al reported that in a type 2 diabetes mouse model, AGES can change bone turnover by binding to their corresponding receptors.30 Rubin et al studied the association between SAF-AGEs and s-PINP, s-CTX, bone-specific alkaline phosphatase (bone ALP), and tartrate-resistant acid

---

**Table 2** (Continued)

| Lipid-lowering agents, n (%) | Total N = 1101 | Without MOFs n = 985 | With MOFs n = 116 | p |
|-----------------------------|----------------|----------------------|------------------|---|
| Statins                     | 373 (33.9%)    | 327 (33.2%)          | 46 (39.7%)       | 0.165 |
| Fibrates                    | 322 (29.2%)    | 280 (28.4%)          | 42 (36.2%)       | 0.081 |
| Ca, n (%)                   | 7 (0.6%)       | 7 (0.7%)             | 0                | 0.589 |
| Calcitriol, n (%)           | 279 (25.3%)    | 252 (25.6%)          | 27 (23.3%)       | 0.862 |
|                           | 273 (24.8%)    | 245 (24.9%)          | 28 (24.1%)       | 0 |

Note: Data are expressed as mean with SD or n (%). The bold values indicates p<0.05.

Abbreviations: AGE, advanced glycation end product; BMI, body mass index; Ca, calcium; DBP, diastolic blood pressure; DPP-IV, dipeptidyl peptidase IV; FPG, fasting plasma glucose; GLP-1, glucagon-like peptide 1; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; MOF, major osteoporotic fracture; P, phosphorus; PG, postload blood glucose; SBP, systolic blood pressure; SGLT2, sodium-glucose cotransporter 2; TC, total cholesterol; TG, triglyceride; UA, uric acid; WHR, waist to hip ratio.
|                  | AGE<sub>age</sub> |          |          |          | Per SD increase | \( p \) for trend |
|------------------|------------------|----------|----------|----------|-----------------|------------------|
|                  | \( \leq 41.66 \) | 41.67–46.37 | 46.38–52.59 | \( \geq 52.60 \) |                 |                 |
| **Total**        |                  |          |          |          |                 |                 |
| No. of patients  | 303              | 304      | 304      | 303      |                 |                 |
| No. of cases     | 53               | 89       | 121      | 171      |                 |                 |
| OR               | 1.00             | 1.95 (1.33–2.87) | 3.12 (2.14–4.54) | 6.11 (4.21–8.88) | 2.11 (1.84–2.43) | <0.001          |
| Multivariable-adjusted OR | 1.00 | 2.02 (1.34–3.03) | 3.63 (2.44–5.39) | 6.51 (4.34–9.78) | 2.22 (1.90–2.58) | <0.001          |
| **Male**         |                  |          |          |          |                 |                 |
| No. of patients  | 109              | 109      | 105      | 118      |                 |                 |
| No. of cases     | 17               | 23       | 30       | 61       |                 |                 |
| OR               | 1.00             | 1.45 (0.72–2.89) | 2.19 (1.11–4.22) | 5.79 (3.08–10.89) | 1.09 (1.07–1.12) | <0.001          |
| Multivariable-adjusted OR | 1.00 | 1.45 (0.70–3.03) | 2.96 (1.45–6.05) | 7.40 (3.62–15.13) | 2.48 (1.89–3.26) | <0.001          |
| **Female**       |                  |          |          |          |                 |                 |
| No. of patients  | 194              | 195      | 199      | 185      |                 |                 |
| No. of cases     | 36               | 66       | 91       | 110      |                 |                 |
| OR               | 1.00             | 2.25 (1.41–3.59) | 3.70 (2.34–5.84) | 6.44 (4.04–10.26) | 1.09 (1.07–1.11) | <0.001          |
| Multivariable-adjusted OR | 1.00 | 2.34 (1.42–3.86) | 4.15 (2.54–6.78) | 6.48 (3.88–10.83) | 2.17 (1.79–2.64) | <0.001          |
| **BMI < 25.0**   |                  |          |          |          |                 |                 |
| No. of patients  | 149              | 161      | 156      | 158      |                 |                 |
| No. of cases     | 26               | 47       | 67       | 91       |                 |                 |
| OR               | 1.00             | 1.95 (1.13–3.56) | 3.56 (2.10–6.04) | 6.43 (3.79–10.89) | 1.09 (1.07–1.11) | <0.001          |
| Multivariable-adjusted OR | 1.00 | 2.13 (1.20–3.76) | 4.49 (2.55–7.88) | 6.34 (3.59–11.21) | 2.09 (1.69–2.58) | <0.001          |
| **BMI \( \geq 25.0 \)** |                  |          |          |          |                 |                 |
| No. of patients  | 153              | 142      | 148      | 145      |                 |                 |
| No. of cases     | 27               | 41       | 54       | 80       |                 |                 |
| OR               | 1.00             | 1.89 (1.09–3.29) | 2.68 (1.57–4.57) | 5.74 (3.38–9.75) | 1.09 (1.07–1.12) | <0.001          |
| Multivariable-adjusted OR | 1.00 | 1.84 (1.02–3.33) | 2.85 (1.61–5.04) | 6.62 (3.65–12.00) | 2.37 (1.89–2.98) | <0.001          |
| **Current smoking (yes)** |                  |          |          |          |                 |                 |
| No. of patients  | 70               | 76       | 59       | 62       |                 |                 |
| No. of cases     | 17               | 26       | 29       | 45       |                 |                 |
| OR               | 1.62 (0.79–3.34) | 3.01 (1.42–6.37) | 8.25 (3.78–18.02) | 2.38 (1.74–3.26) | <0.001          |
| Multivariable-adjusted OR | 1.38 (0.61–3.14) | 3.56 (1.55–8.15) | 6.49 (2.68–15.69) | 2.26 (1.58–3.22) | <0.001          |
| **Current smoking (no)** |                  |          |          |          |                 |                 |
| No. of patients  | 233              | 228      | 245      | 241      |                 |                 |
| No. of cases     | 36               | 63       | 92       | 126      |                 |                 |
| OR               | 2.09 (1.32–3.31) | 3.29 (2.12–5.11) | 6.00 (3.88–9.27) | 2.12 (1.82–2.49) | <0.001          |
| Multivariable-adjusted OR | 2.19 (1.36–3.55) | 3.32 (2.09–5.27) | 5.86 (3.69–9.31) | 2.12 (1.79–2.51) | <0.001          |
| **Current drinking (yes)** |                  |          |          |          |                 |                 |
| No. of patients  | 89               | 89       | 65       | 77       |                 |                 |
| No. of cases     | 20               | 29       | 31       | 51       |                 |                 |
| OR               | 1.67 (0.86–3.25) | 3.15 (1.57–6.31) | 6.77 (3.41–13.44) | 2.29 (1.73–3.02) | <0.001          |
| Multivariable-adjusted OR | 1.76 (0.83–3.73) | 4.24 (1.91–9.38) | 7.82 (3.57–17.13) | 2.44 (1.77–3.35) | <0.001          |
| **Current drinking (no)** |                  |          |          |          |                 |                 |
| No. of patients  | 214              | 215      | 239      | 226      |                 |                 |

(Continues)
phosphatase 5b (TRACP5b) in adults with type 1 diabetes mellitus. They found a positive relationship between SAF-AGEs and all bone turnover markers, but this association was attenuated in adjusted models.

We also identified a relationship between SAF-AGE age and MOFs (mainly hip and vertebral fractures). However, there was no difference in BMD and bone turnover markers (s-PINP and s-CTX) between patients with and without MOFs. In a T-score-stratified analysis for MOFs, we found an association between SAF-AGEs and MOFs in patients without LBD or osteoporosis, but not in those with LBD or osteoporosis. It appears contradictory that SAF-AGE age is negatively associated with BMD and nonlinearly associated with MOFs, but that there is no relationship between BMD and MOF. Lower BMD and active bone turnover are two significant predictors of bone fractures. Therefore, other mechanisms may exist to cause bone fractures by AGEs in T2DM patients. It has been demonstrated that patients with T2DM have a higher incidence of osteosarcopenia and sarcopenia and a lower trabecular bone score (TBS). One animal model study found that a high-AGE diet can destroy the vertebral microarchitecture resulting in vertebral fractures.

Other animal studies have found that the biomechanical properties of the bone matrix are altered by the accumulation of AGEs in the bone of diabetic mice. An in vitro study by Maghami et al found that AGEs can influence the crack-growth trajectory of human cortical bone by promoting crack formation. Piccoli et al found that the accumulation of AGEs in bone tissue can destroy bone microarchitecture in older

| AGEage | ≤41.66 | 41.67–46.37 | 46.38–52.59 | ≥52.60 | Per SD increase | p for trend |
|--------|--------|-------------|-------------|--------|----------------|-------------|
| No. of cases | 33 | 60 | 90 | 120 | | |
| OR | 2.12 (1.32–3.42) | 3.31 (2.10–5.22) | 6.21 (3.94–9.78) | 2.12 (1.80–2.50) | <0.001 |
| Multivariable-adjusted OR | 2.23 (1.35–3.66) | 3.14 (1.95–5.04) | 5.53 (3.412–8.97) | 2.04 (1.71–2.43) | <0.001 |

**Diabetes family history (yes)**

| No. of patients | 192 | 183 | 164 | 151 | | |
| No. of cases | 34 | 52 | 63 | 87 | | |
| OR | 1.00 | 1.85 (1.13–3.01) | 2.90 (1.78–4.71) | 6.32 (3.87–10.33) | 2.27 (1.87–2.77) | <0.001 |
| Multivariable-adjusted OR | 1.00 | 1.80 (1.07–3.04) | 3.25 (1.94–5.46) | 6.60 (3.81–11.41) | 2.40 (1.92–3.00) | <0.001 |

**Diabetes family history (no)**

| No. of patients | 111 | 121 | 140 | 152 | | |
| No. of cases | 19 | 37 | 58 | 84 | | |
| OR | 1.00 | 2.13 (1.14–3.99) | 3.43 (1.88–6.23) | 5.98 (3.32–10.77) | 1.99 (1.63–2.43) | <0.001 |
| Multivariable-adjusted OR | 1.00 | 2.33 (1.20–4.51) | 4.11 (2.18–7.75) | 6.87 (3.63–13.03) | 2.13 (1.71–2.66) | <0.001 |

**Note:** Adjusted for BMI, waist to hip ratio, systolic blood pressure, diastolic blood pressure, fasting plasma glucose, 2-h postload blood glucose, hypertension, current smoking, current drinking, calcium channel blockers, angiotensin receptor blockers, angiotensin-converting enzyme inhibitors, statins, calcium, and calcitriol.

**Abbreviations:** AGE, advanced glycation end product; BMI, body mass index; LBD, low bone density; OR, odds ratio; SAF, skin autofluorescence.
| AGEage | ≤41.73 | 41.74–46.44 | 46.45–52.28 | ≥52.29 | Per SD increase | p for trend |
|--------|--------|-------------|-------------|--------|-----------------|-------------|
| Total  |        |             |             |        |                 |             |
| No. of patients | 276    | 276         | 274         | 275    |                 |             |
| No. of cases   | 18     | 20          | 37          | 41     |                 |             |
| OR              | 1.00   | 1.12 (0.58–2.17) | 2.24 (1.24–4.04) | 2.51 (1.40–4.49) | 1.31 (1.10–1.56) | 0.003       |
| Multivariable-adjusted OR | 1.00   | 1.02 (0.52–2.02) | 2.42 (1.32–4.46) | 2.70 (1.48–4.91) | 1.39 (1.15–1.67) | 0.001       |
| Male           |        |             |             |        |                 |             |
| No. of patients | 98     | 101         | 91          | 105    |                 |             |
| No. of cases   | 6      | 9           | 16          | 7      |                 |             |
| OR              | 1.00   | 1.50 (0.51–4.39) | 3.27 (1.22–8.77) | 1.10 (0.36–3.38) | 1.11 (0.82–1.50) | 0.510       |
| Multivariable-adjusted OR | 1.00   | 1.46 (0.48–4.45) | 4.67 (1.62–13.44) | 1.23 (0.38–4.00) | 1.17 (0.85–1.63) | 0.338       |
| Female         |        |             |             |        |                 |             |
| No. of patients | 178    | 175         | 183         | 170    |                 |             |
| No. of cases   | 12     | 11          | 21          | 34     |                 |             |
| OR              | 1.00   | 0.93 (0.40–2.16) | 1.79 (0.85–3.76) | 3.46 (1.72–6.94) | 1.46 (1.17–1.82) | 0.001       |
| Multivariable-adjusted OR | 1.00   | 0.81 (0.33–1.95) | 1.85 (0.86–3.96) | 3.79 (1.84–7.82) | 1.56 (1.23–1.97) | <0.001      |
| BMI < 25.0      |        |             |             |        |                 |             |
| No. of patients | 137    | 147         | 144         | 140    |                 |             |
| No. of cases   | 9      | 9           | 20          | 27     |                 |             |
| OR              | 1.00   | 0.93 (0.36–2.41) | 2.29 (1.01–5.23) | 3.40 (1.53–7.53) | 1.50 (1.17–1.93) | 0.002       |
| Multivariable-adjusted OR | 1.00   | 0.82 (0.31–2.17) | 2.26 (0.96–5.33) | 3.56 (1.56–8.16) | 1.60 (1.22–2.10) | 0.001       |
| BMI ≥ 25.0      |        |             |             |        |                 |             |
| No. of patients | 138    | 128         | 130         | 135    |                 |             |
| No. of cases   | 9      | 10          | 17          | 14     |                 |             |
| OR              | 1.00   | 1.22 (0.48–3.09) | 2.16 (0.93–5.03) | 1.66 (0.69–3.97) | 1.18 (0.91–1.52) | 0.214       |
| Multivariable-adjusted OR | 1.00   | 1.30 (0.50–3.40) | 2.47 (1.03–5.97) | 1.92 (0.78–4.74) | 1.23 (0.94–1.61) | 0.126       |
| Current drinking (yes) | | | | | | |
| No. of patients | 79     | 82          | 53          | 70     |                 |             |
| No. of cases   | 8      | 8           | 8           | 13     |                 |             |
| OR              | 1.00   | 0.96 (0.34–2.70) | 1.58 (0.55–4.50) | 2.02 (0.79–5.22) | 1.19 (0.89–1.61) | 0.246       |
| Multivariable-adjusted OR | 1.00   | 0.86 (0.29–2.55) | 1.53 (0.51–4.56) | 1.86 (0.67–5.16) | 1.23 (0.87–1.72) | 0.238       |
| Current drinking (no) | | | | | | |
| No. of patients | 197    | 194         | 221         | 205    |                 |             |
| No. of cases   | 10     | 12          | 29          | 28     |                 |             |
| OR              | 1.00   | 1.23 (0.52–2.92) | 2.82 (1.34–5.96) | 2.96 (1.40–6.27) | 1.40 (1.13–1.74) | 0.002       |
| Multivariable-adjusted OR | 1.00   | 1.17 (0.48–2.87) | 3.04 (1.41–6.53) | 3.47 (1.60–7.51) | 1.49 (1.19–1.88) | 0.001       |
| Current smoking (yes) | | | | | | |
| No. of patients | 65     | 74          | 50          | 60     |                 |             |
| No. of cases   | 10     | 10          | 13          | 12     |                 |             |
| OR              | 0.86 (0.33–2.22) | 1.93 (0.77–4.87) | 1.38 (0.55–3.47) | 1.21 (0.87–1.67) | 0.260       |
| Multivariable-adjusted OR | 0.93 (0.35–2.52) | 1.98 (0.73–5.40) | 1.56 (0.58–4.20) | 1.26 (0.89–1.80) | 0.199       |
| Current smoking (no) | | | | | | |
| No. of patients | 211    | 202         | 224         | 215    |                 |             |

(Continues)
women with T2DM by increasing the space between trabeculae and decreasing volumetric BMD.\(^{39}\) Choi Y. J. et al demonstrated that T2DM patients with higher urinary pentosidine have lower TBS.\(^{40}\) Furst et al found that SAF-AGEs are associated with the bone material strength index (BMSi) in T2DM patients.\(^{25}\) These studies may explain the contradiction observed in the present study, by implying the complexity of AGE effects on bone strength.

| AGE\(_{age}\) | \(\leq 41.73\) | 41.74–46.44 | 46.45–52.28 | \(\geq 52.29\) | Per SD increase | \(p\) for trend |
|------------|----------------|----------------|----------------|----------------|----------------|----------------|
| No. of cases | 8 | 10 | 24 | 29 | | |
| OR | 1.32 (0.51–3.42) | 3.05 (1.34–6.94) | 3.96 (1.76–8.87) | 1.42 (1.15–1.76) | 0.001 |
| Multivariable-adjusted OR | 1.22 (0.46–3.24) | 3.40 (1.47–7.84) | 4.53 (1.99–10.32) | 1.51 (1.21–1.88) | <0.001 |

**TABLE 4** (Continued)

**LBD or osteoporosis (yes)**

| | \(\leq 41.73\) | 41.74–46.44 | 46.45–52.28 | \(\geq 52.29\) | Per SD increase | \(p\) for trend |
| | 4 | 8 | 9 | 21 | | |
| OR | 1.20 (0.34–4.21) | 1.03 (0.30–3.53) | 1.76 (0.58–5.41) | 1.09 (0.82–1.44) | 0.564 |
| Multivariable-adjusted OR | 1.14 (0.30–4.29) | 0.99 (0.28–3.55) | 1.82 (0.57–5.83) | 1.17 (0.85–1.60) | 0.332 |

**TABLE 4** (Continued)

**LBD or osteoporosis (no)**

| | \(\leq 41.73\) | 41.74–46.44 | 46.45–52.28 | \(\geq 52.29\) | Per SD increase | \(p\) for trend |
| | 14 | 12 | 28 | 20 | | |
| OR | 1.01 (0.46–2.24) | 3.07 (1.56–6.03) | 3.04 (1.48–6.27) | 1.69 (1.30–2.20) | <0.001 |
| Multivariable-adjusted OR | 0.89 (0.39–2.02) | 3.74 (1.84–7.62) | 3.78 (1.77–8.07) | 1.84 (1.39–2.43) | <0.001 |

**TABLE 5** Association of SAF-AGEs (per 10 units) with s-PINP and s-CTX among patients with type 2 diabetes

| | s-PINP, ng/mL | s-CTX, ng/mL |
| | OR (95% CI) | \(p\) | OR (95% CI) | \(p\) |
| Univariate model | 1.09 (0.31–1.87) | 0.006 | 5.60 (1.35–10.64) | 0.011 |
| Adjusted model | 1.02 (0.24–1.80) | 0.011 | 6.30 (1.77–10.83) | 0.006 |

**TABLE 5** Association of SAF-AGEs (per 10 units) with s-PINP and s-CTX among patients with type 2 diabetes

**Note:** Adjusted model by sex, body mass index, HbA1c, and age. 
Abbreviations: AGE, advanced glycation end product; HbA1c, glycosylated hemoglobin; OR, odds ratio; SAF, skin autofluorescence; s-CTX, serum carboxy-terminal cross-linking peptide of type I collagen; s-PINP, serum N-terminal propeptide of type I procollagen.

**FIGURE 3** The spline association between SAF-AGE\(_{age}\) levels and MOFs

**Note:** Adjusted for sex, BMI, diastolic blood pressure, hypertension, current smoking, current drinking, calcium channel blockers, statins, and serum triglycerides other than the variable for stratification.
Abbreviations: AGE, advanced glycation end product; BMI, body mass index; LBD, low bone density; MOF, major osteoporotic fracture; OR, odds ratio; SAF, skin autofluorescence.
Higher serum pentosidine in T2DM patients with vertebral fractures has been reported in some studies.\(^{41,42}\) Although we used different variables (SAF-AGE\(_{\text{age}}\) and serum pentosidine) and different fracture sites, we showed similar results. However, in contrast with our results, the Rotterdam study found no association between SAF-AGE\(_{\text{age}}\) and MOFs or vertebral fractures in T2DM patients.\(^{15}\) Several factors may underlie these contradictory findings. First, the time of SAF measurement was different. In our study, SAF measurement preceded the MOF follow-up. Second, the inclusion criteria were somewhat different; we excluded individuals with conditions such as end-stage kidney disease and malignancy that may affect bone metabolism, thereby reducing possible sources of confounding. Third, the assessed fracture sites (MOFs of the hip, vertebrae wrist, or humerus versus vertebral fractures only in patients with T2DM) were different. Finally, the sample size of T2DM patients was different. Although the Rotterdam study had a large total sample size, the number of subjects with T2DM was relatively small (353 vs 1214 in our study), thereby suggesting that our results are more generalizable to the population.

Following stratification by smoking and drinking status, we found an association between SAF-AGEs and MOFs in nonsmokers and nondrinkers, but not in current smokers and current drinkers. Some studies have demonstrated the association between current smoking or alcohol consumption and SAF-AGEs,\(^{43-46}\) but we did not observe this association. Some potential factors may exist. First, the majority of smokers and drinkers in our study were older men. Second, there is marked heterogeneity in cigarette and alcohol type and quantity between different studies, which may lead to inconsistent results. Finally, the mechanism by which cigarettes and alcohol affect bone fractures is complex and comprehensive.\(^{47,48}\) Following the stratified analysis by sex, we found that SAF-AGEs were associated with MOFs in women but not in men, which was consistent with the Rotterdam study general population results.\(^{15}\)

There are some limitations to the present study. First, the loss to follow-up for MOFs was 9.3% due to incorrect contact details, death, no response, etc. Second, the enrolled individuals were from two communities located in urban Beijing. The results obtained from these individuals may be generalizable to at least the wider middle-aged and elderly Beijing and Chinese T2DM population. However, further work is required to confirm the generalizability of our findings.

In conclusion, we found that SAF-AGE\(_{\text{age}}\) is positively associated with the prevalence of LBD/osteoporosis in patients with T2DM. We also found a positive association between SAF-AGEs and s-PINP and s-CTX. There was an association between SAF-AGE\(_{\text{age}}\) and the incidence of MOFs that was independent of BMD. Larger prospective studies are still needed to explore the effects of AGEs on bone fractures in T2DM patients.

**AUTHOR CONTRIBUTIONS**

Hongyan Liu and Guoqi Wang analyzed the data. Hongyan Liu was a major contributor in writing the manuscript. Guoqi Wang performed the statistical analysis. Ting Wu and Jia Hu searched data. Weijun Gu and Yiming Mu were the superior advisors. They gave final approval of the version to be published. All authors read and approved the final manuscript.

**ACKNOWLEDGEMENTS**

We thank all participants and their families for participating in this study.

**FUNDING INFORMATION**

This study was supported by the National Key R&D Program of China (project no. 2016YFC1305200).

**CONFLICT OF INTEREST**

The authors declare no conflicts of interest in this work.

**DATA AVAILABILITY STATEMENT**

The datasets used to support this study are not freely available in view of participants’ privacy protection.

**PATIENT CONSENT STATEMENT**

Written informed consent was obtained from all participants prior to participation.

**PERMISSION TO REPRODUCE MATERIAL FROM OTHER SOURCES**

There is no material from other sources.

**ORCID**

Hongyan Liu https://orcid.org/0000-0002-2864-9034

Weijun Gu https://orcid.org/0000-0001-8690-645X

**REFERENCE**

1. Consensus development conference. Diagnosis, prophylaxis, and treatment of osteoporosis. *Am J Med.* 1993;94:646-650.
2. Amin S, Achenbach SJ, Atkinson EJ, Khosla S, Melton LJ 3rd. Trends in fracture incidence: a population-based study over 20 years. *J Bone Miner Res.* 2014;29:581-589.
3. Daffner SD, Karnes JM, Watkins CM. Surgeon specialty influences referral rate for osteoporosis management following vertebral compression fractures. *Global Spine J.* 2016;6:524-528.
4. Si Y, Wang C, Guo Y, Xu G, Ma Y. Prevalence of osteoporosis in patients with type 2 diabetes mellitus in the Chinese mainland: a systematic review and meta-analysis. *Iran J Public Health.* 2019;48:1203-1214.
5. Wang H, Ba Y, Xing Q, Du JL. Diabetes mellitus and the risk of fractures at specific sites: a meta-analysis. *BMJ Open.* 2019;9:e024067.
6. Kuzan A. Toxicity of advanced glycation end products (Review). Biomed Rep. 2021;14:46.

7. Conway BN, Aroda VR, Maynard JD, et al. Skin intrinsic fluorescence is associated with coronary artery disease in individuals with long duration of type 1 diabetes. Diabetes Care. 2012;35:2331-2336.

8. Boyer F, Vidot JB, Dubourg AG, Rondeau P, Essop MF, Bourdon E. Oxidative stress and adipocyte biology: focus on the role of AGEs. Oxid Med Cell Longev. 2015;2015:534873.

9. Cortizo AM, Lettieri MG, Barrio DA, Mercer N, Etcheverry SB, McCarthy AD. Advanced glycation end-products (AGEs) induce concerted changes in the osteoblastic expression of their receptor RAGE and in the activation of extracellular signal-regulated kinases (ERK). Mol Cell Biochem. 2003;250:1-10.

10. Hein G, Wiegand R, Lehmann G, Stein G, Franke S. Advanced glycation end-products pentosidine and N epsilon-carboxymethyllysine are elevated in serum of patients with osteoporosis. Rheumatology (Oxford). 2003;42:1242-1246.

11. Choi DH, Lee SM, Lim SA, Choi YS. Feasibility of serum Pentosidine level as a potential risk factor for osteoporotic vertebral compression fracture. Asian Spine J. 2018;12:992-997.

12. Meerwaldt R, Graaff R, Oomen PHN, et al. Simple non-invasive assessment of advanced glycation endproduct accumulation. Diabetologia. 2004;47:1324-1330.

13. Meerwaldt R, Hartog JW, Graaff R, et al. Skin autofluorescence, a measure of cumulative metabolic stress and advanced glycation end products, predicts mortality in hemodialysis patients. J Am Soc Nephrol. 2005;16:3687-3693.

14. Tabara Y, Ikekoe T, Yamanaka M, et al. Advanced glycation end product accumulation is associated with low skeletal muscle mass, weak muscle strength, and reduced bone density: the Nagahama study. J Gerontol A Biol Sci Med Sci. 2019;74:1446-1453.

15. Waqas K, Chen J, Koromani F, et al. Skin autofluorescence, a noninvasive biomarker for advanced glycation end-products, is associated with prevalent vertebral and major osteoporotic fractures: the Rotterdam study. J Bone Miner Res. 2020;35:1904-1913.

16. Ning G. Risk Evaluation of cancers in Chinese diabetic individuals: a IONGitudinal (REACTION) study. J Diabetes. 2012;4:172-173.

17. Raška I Jr, Rašková M, Zikán V, Škrha J. Prevalence and risk factors of osteoporosis in postmenopausal women with type 2 diabetes mellitus. Cent Eur J Public Health. 2017;25:3-10.

18. Yavuz DG, Apaydın T. Skin autofluorescence is associated with low bone mineral density in type 2 diabetic patients. J Clin Densitom. 2022;25:373-379.

19. Saito M, Marumo K. Collagen cross-links as a determinant of bone quality: a possible explanation for bone fragility in aging, osteoporosis, and diabetes mellitus. Osteoporos Int. 2010;21:195-214.

20. Vigué-Carrin S, Roux JP, Arlot ME, et al. Contribution of the advanced glycation end product pentosidine and of maturation of type I collagen to compressive biomechanical properties of human lumbar vertebrae. Bone. 2006;39:1073-1079.

21. Oxlund H, Moskilde L, Ortoft G. Reduced concentration of collagen reducible cross links in human trabecular bone with respect to age and osteoporosis. Bone. 1996;19:479-484.

22. Takata T, Sakasai-Sakai A, Takeuchi M. Impact of intracellular toxic advanced glycation end-products (TAGE) on murine myoblast cell death. Diabetol Metab Syndr. 2020;12:54.

23. Shu A, Yin MT, Stein E, et al. Bone structure and turnover in type 2 diabetes mellitus. Osteoporos Int. 2012;23:635-641.

24. Gerdmeh P, Isaksenn A, Aekssen K, Obrant KJ. Increased bone density and decreased bone turnover, but no evident alteration of fracture susceptibility in elderly women with diabetes mellitus. Osteoporos Int. 2005;16:1506-1512.

25. Furst JR, Bandeira LC, Fan WW, et al. Advanced glycation Endproducts and bone material strength in type 2 diabetes. J Clin Endocrinol Metab. 2016;101:2502-2510.

26. Park SY, Choi KH, Jun JE, Chung HY. Effects of advanced glycation end products on differentiation and function of osteoblasts and osteoclasts. J Korean Med Sci. 2021;36:e239.

27. Lee EJ, Kang MK, Kim YH, et al. Coumarin ameliorates impaired bone turnover by inhibiting the formation of advanced glycation end products in diabetic osteoblasts and osteoclasts. Biomolecules. 2020;10:1052.

28. Tanaka K, Yamaguchi T, Kanazawa I, Sugimoto T. Effects of high glucose and advanced glycation end products on the expressions of sclerostin and RANKL as well as apoptosis in osteocyte-like MLO-Y4-A2 cells. Biochem Biophys Res Commun. 2015;461:193-199.

29. Lamb LS, Alfonso H, Norman PE, et al. Advanced glycation end products and esRAGE are associated with bone turnover and incidence of hip fracture in older men. J Clin Endocrinol Metab. 2018;103:4224-4231.

30. Eckhardt BA, Rowsey JL, Thicke BS, et al. Accelerated osteocyte senescence and skeletal fragility in mice with type 2 diabetes. JCI Insight. 2020;5:e135236.

31. Rubin MR, de Boer IH, Backlund JC, et al. Biochemical markers of bone turnover in older adults with type 1 diabetes. J Clin Endocrinol Metab. 2022;107:e2405-e2416.

32. Pechmann LM, Petterle RR, Moreira CA, Borba VZC. Osteosarcoenia and trabecular bone score in patients with type 2 diabetes mellitus. Arch Endocrinol Metab. 2021;65:801-810.

33. Dhaliwal R, Cibula D, Ghosh C, Weinstock RS, Moses AM. Bone quality assessment in type 2 diabetes mellitus. Osteoporos Int. 2014;25:1969-1973.

34. Holloway KL, De Abreu LLF, Hans D, et al. Trabecular bone score in men and women with impaired fasting glucose and diabetes. Calcif Tissue Int. 2018;102:32-40.

35. Illien-Jünger S, Palacio-Mancheno P, Kindschuh WF, et al. Dietary advanced glycation end products have sex- and age-dependent effects on vertebral bone microstructure and mechanical function in mice. J Bone Miner Res. 2018;33:437-448.

36. Saito M, Marumo K. Effects of collagen crosslinking on bone material properties in health and disease. Calcif Tissue Int. 2015;97:242-261.

37. Odetti P, Rossi S, Monacci F, et al. Advanced glycation end products and bone loss during aging. Ann N Y Acad Sci. 2005;1043:710-717.

38. Maghari E, Josephson TO, Moore JP, et al. Fracture behavior of human cortical bone: role of advanced glycation end-products and microstructural features. J Biomech. 2021;125:110600.
39. Piccoli A, Cannata F, Strollo R, et al. Sclerostin regulation, microarchitecture, and advanced glycation end-products in the bone of elderly women with type 2 diabetes. J Bone Miner Res. 2020;35:2415-2422.

40. Choi YJ, Ock SY, Jin Y, Lee JS, Kim SH, Chung Y. Urinary Pentosidine levels negatively associates with trabecular bone scores in patients with type 2 diabetes mellitus. Osteoporos Int. 2018;29:907-915.

41. Yamamoto M, Yamaguchi T, Yamauchi M, Yano S, Sugimoto T. Serum pentosidine levels are positively associated with the presence of vertebral fractures in postmenopausal women with type 2 diabetes. J Clin Endocrinol Metab. 2008;93:1013-1019.

42. Schwartz AV, Garnero P, Hillier TA, et al. Pentosidine and increased fracture risk in older adults with type 2 diabetes. J Clin Endocrinol Metab. 2009;94:2380-2386.

43. van Waateringe RP, Slagter SN, van der Klauw MM, et al. Lifestyle and clinical determinants of skin autofluorescence in a population-based cohort study. Eur J Clin Invest. 2016;46:481-490.

44. Kellow NJ, Coughlan MT, Reid CM. Association between habitual dietary and lifestyle behaviours and skin autofluorescence (SAF), a marker of tissue accumulation of advanced glycation end-products (AGEs), in healthy adults. Eur J Nutr. 2018;57:2209-2216.

45. Botros N, Sluik D, van Waateringe RP, de Vries JHM, Geelen A, Feskens EJM. Advanced glycation end-products (AGEs) and associations with cardio-metabolic, lifestyle, and dietary factors in a general population: the NQplus study. Diabetes Metab Res Rev. 2017;33:e2892.

46. den Engelsen C, van den Donk M, Gorter KJ, Salomé PL, Rutten GE. Advanced glycation end products measured by skin autofluorescence in a population with central obesity. Derma- toendoocrinol. 2012;4:33-38.

47. Eby JM, Sharieh F, Callaci JJ. Impact of alcohol on bone health, homeostasis and fracture repair. Curr Pathobiol Rep. 2020;8:75-86.

48. Yuan S, Michaëlsson K, Wan Z, Larsson SC. Associations of smoking and alcohol and coffee intake with fracture and bone mineral density: a Mendelian randomization study. Calcif Tissue Int. 2019;105:582-588.

How to cite this article: Liu H, Wang G, Wu T, Hu J, Mu Y, Gu W. Association of skin autofluorescence with low bone density/osteoporosis and osteoporotic fractures in type 2 diabetes mellitus. Journal of Diabetes. 2022;14(9):571-585. doi:10.1111/1753-0407.13309